A Long Term Follow-Up Study for Subjects Who Have Received Q-Cells
NCT06163508 is an observational study sponsored by University of Texas Southwestern Medical Center. As of 21 Nov 2026, it is enrolling by invitation only. It studies Q-Cells® in Transverse Myelitis. The registry lists an enrollment of 9 participants at 1 site in 1 country. The registry lists a start date of 12 Dec 2023 and a primary completion date of 31 Dec 2035.
Key facts
Registry attributes as recorded on the ClinicalTrials.gov study record.
| Field | Value |
|---|---|
| Registry ID | NCT06163508 |
| Status | Enrolling by invitation |
| Study type | Observational study |
| Lead sponsor | University of Texas Southwestern Medical Center |
| Enrollment | 9 |
| Registered sites | 1 |
| Countries | 1 |
| Conditions | Transverse Myelitis |
| Drugs | Q-Cells® |
| Start | 12 Dec 2023 |
| Primary completion | 31 Dec 2035 |
| Study completion | 31 Dec 2035 |
| Last update posted | 21 Apr 2026 |
Registered summary
The lay summary the sponsor registered on ClinicalTrials.gov.
Investigators
The overall officials registered on this study. Names that resolve to a FindMyKOL profile link to it; the rest are shown as registered.
- Benjamin Greenberg, MD
University of Texas Southwestern Medial Center
Principal Investigator
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
1 registered facility, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- the University of Texas Southwestern Medical Center
Dallas
United States, by state
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.
Questions about NCT06163508
Each answer restates registry values shown on this page.
What is NCT06163508?
NCT06163508 is an observational study sponsored by University of Texas Southwestern Medical Center. It studies Q-Cells® in Transverse Myelitis.
Is NCT06163508 recruiting?
As of 21 Nov 2026, it is enrolling by invitation only.
Who leads NCT06163508?
The registry names Benjamin Greenberg, MD (principal investigator, University of Texas Southwestern Medial Center) as the overall official.
Where does NCT06163508 run?
The registry lists 1 site in 1 country. Every site with a stated country is in one country: United States.
Which drugs does NCT06163508 study?
The registered drug and biological interventions are Q-Cells®.
When is NCT06163508 expected to complete?
The registry lists a primary completion date of 31 Dec 2035 and a study completion date of 31 Dec 2035. The sponsor last updated the record on 21 Apr 2026.
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 21 Nov 2026. Registry facts are shown as registered by the study sponsor; FindMyKOL does not interpret them.